天坛生物连跌4天，易方达基金旗下1只基金位列前十大股东

Core Viewpoint - Tian Tan Biological has experienced a decline in stock price over the past four trading days, with a cumulative drop of -5.57% [1] Company Overview - Beijing Tian Tan Biological Products Co., Ltd. was listed in 1998 and specializes in the research, manufacturing, sales, and consulting services of blood products [1] Shareholder Information - E Fund's E Fund CSI 300 Pharmaceutical ETF has entered the top ten shareholders of Tian Tan Biological, marking a new entry in the fourth quarter of last year [1] - The fund manager of E Fund's CSI 300 Pharmaceutical ETF is Yu Haiyan, who has extensive experience in investment management [4][5] Performance Metrics - The year-to-date return for the E Fund CSI 300 Pharmaceutical ETF is -3.41%, ranking 2040 out of 3440 in its category [1] - Recent performance metrics show a weekly increase of 0.84%, a monthly decrease of -4.94%, and a quarterly increase of 1.67% [2]